Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes DiseaseGlobeNewsWire • 12/07/21
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/15/21
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/01/21
Fortress Biotech to Participate in Dawson James Securities' 6th Annual Small Cap Growth ConferenceGlobeNewsWire • 10/18/21
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & ExhibitionPRNewsWire • 10/13/21
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZenecaGlobeNewsWire • 10/06/21
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial OfficerGlobeNewsWire • 10/05/21
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress BiotechGlobeNewsWire • 09/29/21
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/16/21
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/02/21
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease TherapeuticsBenzinga • 06/03/21
Fortress Biotech to Participate in Three June 2021 Virtual Investor ConferencesGlobeNewsWire • 06/01/21
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/17/21
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/16/21